A “standardized,” on-line calculator for PSADT

PSA doubling time or PSADT is a valuable prognostic factor in assessing the need for second- or even third-line treatment in men with biochemical progression of prostate cancer. … READ MORE …

Biochemical recurrence after RP and risk of mortality

A recent report in Cancer again seems to suggest that men with prostate cancer treated by radical prostatectomy (RP) who have a long time to biochemical recurrence (BCR) or a long PSA doubling time after BCR may have no higher overall risk of death than men who have no BCR at all. … READ MORE …

New nomogram can predict aggressive recurrence after RP

Researchers associated with the Duke Prostate Cancer have re-calibrated an older nomogram (used to predict the likelihood of biochemical recurrence after a radical prostatectomy or RP). The revised nomogram is now capable of predicting not only biochemical recurrence but also the much more clinically significant risk for an aggressive recurrence — in which the post-surgical PSA doubling time (PSADT) is < 9 months. … READ MORE …

Prostate cancer recurrence, PSADT, and patient comorbidities

D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men with other “comorbid” health problems. … READ MORE …

How early can PSA doubling times tell what?

A new study from a group at Duke University has attempted to assess whether data based on PSA doubling times in men with PSA levels up to 0.2 ng/ml can be used as effectively to make early treatment decisions for men with a rising PSA after first-line therapy as can PSA doubling times for men with PSA levels higher than 0.2 ng/ml. … READ MORE …

PSA kinetics and prediction of outcomes of untreated patients

There has been an on-going difference of opinion within sections of the urology community regarding the value of PSA velocity and/or PSA doubling times in predicting outcomes to first-line prostate cancer treatment. … READ MORE …

Your Monday News update: November 17, 2008

We apologize to readers the lack of a weekend news report due to travel constraints, but this report will include all the past 3 days news that we are aware of, including:

  • The relative value of PSAV and PSADT in predicting risk for positive results on rebiopsy
  • Prostate size and brachytherapy
  • Microspcopic bladder neck invasion of prostatectomy specimens
  • Early chemohormonal therapy + radiotherapy for high-risk patients … READ MORE …